Skip to content

Chambá: an useful medicine in the treatment of high blood pressure?

Evaluation of JP002 in the treatment of individuals with Hypertension: randomized, double-blind, placebo-controlled clinical trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
REBEC
Registry ID
RBR-5tsy7yx
Enrollment
Unknown
Registered
2021-05-27
Start date
2021-07-05
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Patients will be randomly allocated and double-blind in the control group (n = 53) or in the treatment group (n = 53). The treatment group will receive tincture prepared with Justicia pectoralis leave
32339
59046

Sponsors

Faculdade de Medicina de Ribeirão Preto -USP
Lead Sponsor
Faculdade de Medicina de Ribeirão Preto -USP
Collaborator

Eligibility

Age
12 Years to 80 Years

Inclusion criteria

Inclusion criteria: Men, non-pregnant women, older than 12 years old and less than or equal to 80 years old, diagnosed with Hypertension and on at least monotherapy regimen for this disease.

Exclusion criteria

Exclusion criteria: Pregnant or lactating women; hypertension due to secondary cause; coagulopathies; individuals who use any other herbal medicine during the study; individuals who have a serious adverse reaction to the medication, individuals who request their withdrawal from the study.

Design outcomes

Primary

MeasureTime frame
The main outcome of the study will be the decrease of at least 10 mm Hg in the mean systolic blood pressure of 24 hours verified by ambulatory blood pressure monitoring in the treatment group and 60 days after the intervention. Data collected before the start of treatment and 60 days after.

Secondary

MeasureTime frame
Secondary outcomes will be: decreased arterial stiffness in the treatment group verified by decrease in pulse wave velocity in relation to the placebo group after 60 days of intervention. Procedure performed one day before the start of treatment and 60 days after treatment; increase in nitrite and nitrosothio levels in relation to baseline in the treatment group quantified in plasma after 60 days of intervention. Dosage performed one day before the start of treatment and 60 days after treatment.

Countries

Brazil

Contacts

Public ContactLucas Chaves
l.chaves@usp.br+5516981915134

Outcome results

None listed

Source: REBEC (via WHO ICTRP)